Across the Nutraverse: US supplement usage, OmniActive’s new acquisition, SABPA report, and more

The-Nutraverse-CRN-s-supplement-survey-OmniActive-s-new-acquisition-SABPA-report-NPA-on-NMN.jpg

A lot has happened in the global nutrition industry over the past seven days, with headlines including data from CRN’s annual consumer survey, OmniActive’s recent M&A activity, NPA celebrating NMN success, and the inaugural SABPA symposium. Catch up with our weekly round-up of key news from across the Nutraverse.

USA: Supplement use remains at 75%, interest increases in specialty products

Three quarters of Americans continue to use dietary supplements, according to the 2024 Consumer Survey conducted by Ipsos and sponsored by the Council for Responsible Nutrition.

This is consistent with 2023 numbers, but CRN noted that the survey highlights subtle shifts towards specific products as the market moves toward precision health approaches.

“We continue to see consumers exploring new specialty products and embrace personalized health solutions,” said Jeff Ventura, senior vice president of communications at CRN. “This speaks to the evolving landscape of wellness, where supplements are becoming more integrated into individualized health practices.”

According to the survey, 69% of respondents said they look for a personalized regimen when choosing their products. Among users under the age of 55, Black and Asian Americans are more likely seek out personalized solutions when selecting a dietary supplement.

The reasons for supplement use remain also consistent with 2023 data—42% of consumers list overall health and wellness as a motivation for supplementation. Immune health and energy are factors contributing to use in 30% and 27% of consumers, respectively.

Click HERE for more information.

India: OmniActive acquires ENovate Biolife

OmniActive Health Technologies has acquired ENovate Biolife, expanding its ingredients portfolio to target key health categories in the dietary supplement space.

The agreement, finalized on Oct. 26, builds on the success of an initial 2019 partnership between the two companies through a U.S. licensing agreement for enXtra, a clinically studied Alpinia Galanga ingredient marketed to support mental energy.

“We are extremely proud of the strides we have made to help our loyal customers deliver products formulated with clinically backed ingredients to address consumer health and performance needs,” said Jayesh Chaudhary, founder and CEO of ENovate.

“OmniActive’s comprehensive capabilities spanning across clinical research, R&D, regulatory, marketing and operations, along with global reach, position us well to elevate these ingredients even further.”

Read the full story on NutraIngredients-Asia.

USA: NPA celebrates ‘monumental victory’ in NMN action

The Natural Products Association (NPA) is celebrating after a federal court granted a joint motion to stay proceedings in a lawsuit to allow the Food and Drug Administration to respond to a Citizen Petition that may resolve the case about Nicotinamide Mononucleotide (NMN) without further litigation.

The decision added the FDA will not be pursue unauthorized punitive and disciplinary measures on NMN products during the stay. In terms of the the Citizen Petition, filed by NPA and the Alliance for Natural Health (ANH) in March 2023, the Court requires the FDA to respond by the end of July 2025.

Speaking with NutraIngredients-USA at the recent SupplySide West, Dr. Daniel Fabricant, NPA’s CEO and president, said: “We worked with the government to make some changes to the citizen petition as well as our case, and so the agency can respond to everything.

“Also, it gives us a period of enforcement discretion. Obviously, folks are selling NMN [and they still] have to adhere to the other parts of the Food, Drug and Cosmetic Act, but the government will not be prioritizing any enforcement on NMN as an ingredient during that time period.

“I think that bodes well, considering the history, some shades of NAC too. So, stay tuned.”

Southern Africa: Inaugural SABPA symposium explores access to and benefit sharing for region’s botanicals

Dr. Thomas Brendler, founding member SABPA, shared the highlights of the first Southern African Botanical Products Association (SABPA) symposium, which was attended by over 80 stakeholders from government, academia and industry.

The schedule for the one-day symposium, held in Cape Town, South Africa on Oct. 23, centered on the dire need for closing knowledge gaps on issues such as innovative ways to protect indigenous knowledge, bringing botanical ingredients and products to market and maximizing the novel value of botanicals from this region. Emphasis was on topics linked to five pillars of commercialization:

- Know your ingredient/product

- Respect traditional knowledge

- Secure your supply chain

- Comply with regulations

- Understand your market

To read the full report, please click HERE.